Promising anti-tumor activity reported for C-CAR031, a novel Glypican 3 (GPC3)-targeting cell therapy designed by AstraZeneca (AZN) SHANGHAI, April 17, 2023 /PRNewswire/ -- Shanghai Cellular ...
SHANGHAI, April 17, 2023 /CNW/ -- Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development of immunotherapies for cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results